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Mast cells (MCs) are tissue resident cells of hemopoietic origin and are critically involved in allergic diseases. MCs
bind IgE by means of their high-affinity receptor for IgE (FcεRI). The FcεRI belongs to a family of multi-chain
immune recognition receptors and is activated by cross-linking in response to multivalent antigens (Ags)/allergens.
Activation of the FcεRI results in immediate release of preformed granular substances (e.g. histamine, heparin, and
proteases), generation of arachidonic acid metabolites, and production of pro-inflammatory cytokines. The FcεRI
shows a remarkable, bell-shaped dose-response behavior with weak induction of effector responses at both low
and high (so-called supra-optimal) Ag concentrations. This is significantly different from many other receptors,
which reach a plateau phase in response to high ligand concentrations. To explain this unusual dose-response
behavior of the FcεRI, scientists in the past have drawn parallels to so-called precipitin curves resulting from
titration of Ag against a fixed concentration of antibody (Ab) in solution (a.k.a. Heidelberger curves). Thus, for high,
supra-optimal Ag concentrations one could assume that every IgE-bound FcεRI formed a monovalent complex with
“its own Ag”, thus resulting in marginal induction of effector functions due to absence of receptor cross-linking.
However, this was never proven to be the case. More recently, careful studies of FcεRI activation and signaling
events in MCs in response to supra-optimal Ag concentrations have suggested a molecular explanation for the
descending part of this bell-shaped curve. It is obvious now that extensive FcεRI/IgE/Ag clusters are formed and
inhibitory molecules and signalosomes are engaged in response to supra-optimal cross-linking (amongst them the
Src family kinase Lyn and the inositol-50-phosphatase SHIP1) and they actively down-regulate MC effector
responses. Thus, the analysis of MC signaling triggered by supra-optimal crosslinking holds great potential for
identifying novel targets for pharmacologic therapeutic intervention to benefit patients with acute and chronic
allergic diseases.
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Mast cells are central players in allergic diseases like hay
fever and asthma. When allergens bind to specific
receptors (called FcεRI) on the surface of mast cells,
various intracellular events are triggered, resulting in the
secretion of inflammatory mediators, such as histamine
and proteases. These mediators are responsible for the
well known symptoms of allergies (e.g. itching, sneezing,
and coughing). In principle, receptors for different
ligands are expressed by every cell, enabling each cell to
sense its environment and react to it in an appropriateCorrespondence: mhuber@ukaachen.de
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reproduction in any medium, provided the orfashion. Usually, the concentration of the ligand
correlates with the extent of the ligand-induced cellular
response. Intriguingly, this is not the case for the FcεRI.
High, so-called supra-optimal allergen concentrations
result in only weak activation of mast cells, whereas
lower concentrations of allergen can cause strong activa-
tion. The reason is that high allergen concentrations
engage inhibitory mechanisms, which do not allow for
the induction of mediator secretion. In recent years, sev-
eral intracellular proteins involved in such inhibitory
mechanisms have been identified and their functional
interactions are currently being elucidated. Thus, further
investigation of this cell-intrinsic shut-off mechanism
and identification of additional proteins involved shouldis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pharmacologic intervention. The aim would be to ex-
ploit this knowledge to actively silence the mast cell dur-
ing pollen season.
Review
The cell and its receptor
Mast cells (MCs) are hemopoietically derived tissue
resident cells that are concentrated in tissues close to
the external environment, i.e., the skin and mucosal
membranes of the intestine and airways [1]. One of their
main functions is to act as guards, alerting the body to
invasion by bacteria, parasites and viruses and initiating
an inflammatory response [2-5]. On the pathophysio-
logical side, amongst others MCs have attained inglori-
ous publicity as central effector cells in acute allergic






Figure 1 The FcεRI and its dose-response behavior. (A) The murine Fcε
subunit contains only a short cytoplasmic region and binds to the constan
domain (oval shape). The β-subunit belongs to the tetraspanin family and
Due to its association with further activating Fc receptors the γ-subunit is n
their cytoplasmic regions. The ITAMs are phosphorylated by Lyn (visualized
Lyn has been shown to be pre-associated with the FcεRI. PM, plasma mem
amounts of respective ligands usually results in a saturation of the respons
FcεRI traverses through three distinct phases. At low Ag concentrations, i. e
medium Ag concentrations (the zone of equivalence between Ab and Ag)
i. e. a low Ab/Ag ratio, only a weak response can again be measured. Thereantigens (Ags) via IgE immunoglobulins, which are bound
to high-affinity IgE receptors (FcεRI) on the surface of the
MCs. Ag-triggered activation of the FcεRI then results in
several pro-inflammatory responses, such as release of
preformed mediators (e.g. histamine, proteoglycans, and
proteases) from intracellular granules in a process called
degranulation, and de-novo production and release of
arachidonic acid metabolites (e.g. leukotrienes and
prostaglandins) as well as cytokines and chemokines (e.g.
IL-6, TNF-alpha and MCP-1) [7]. As a result, MCs play a
central role in the development of type I hypersensitivity
reactions [8,9].
The FcεRI on murine MCs and basophils consists of
an α-subunit, a β-subunit, and two disulfide-bridged γ-
subunits (αβγ2) [10] (Figure 1A). The α-subunit, which
contains only a short cytoplasmic tail of 17 amino acids,
binds to the constant Cε3 region of the IgE molecule viaC
IgE
Ag
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t Cε3 region of IgE via its second extracellular immunoglobulin-like
the γ-subunits can be called small transmembrane adaptor proteins.
ow called FcRgamma. β-subunit and FcRgamma contain ITAMs in
by red ovals) subsequent to receptor crosslinking by multivalent Ag.
brane. (B) Stimulation of growth factor receptors with increasing
e at high ligand concentrations. (C) The dose–response curve of the
. a high Ab/Ag ratio, only a weak response can be measured, at
an optimal response can be observed, and at high Ag concentrations,
fore, this dose–response curve is called bell-shaped.
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[11]. The β-subunit, a tetraspanin, and the γ-subunits
contain immunoreceptor tyrosine-based activation
motifs (ITAMs) in their cytoplasmic domains [12],
which, when phosphorylated by the Src family kinase
(SFK) Lyn after receptor crosslinking by multivalent Ag,
trigger signaling events by attracting cytoplasmic
proteins that contain phosphotyrosine-binding SH2-
domains [7]. Lyn has been shown to be pre-associated
with the FcεRI [13,14]. Of note, the γ-subunit of the
FcεRI also associates with other activating Fc receptors
and therefore is now referred to as FcRgamma [15].
Though the IgE Fc-fragment is dimeric by nature, IgE-
induced crosslinking of FcεRIs does not occur in the ab-
sence of Ag. Interaction of IgE with the α-subunit of one
FcεRI prohibits concomitant binding to a second FcεRI
α-subunit [16]. Moreover, extensive glycosylation of the
FcεRI α-subunit is thought to suppress spontaneous ag-
gregation of the FcεRI [7]. Thus, activation requires
crosslinking of two or more IgE-bound receptors by
multivalent Ag. However, binding of IgE to the FcεRI is
not a mere passive presensitization step to confer Ag
specificity on the MC, but rather it induces Ag-
independent signaling events that actively promote MC
survival [17-19]. For completeness, it has to be added
that whereas the FcεRI on murine MCs always contains
the β-chain [10], the FcεRI can be expressed in two
forms in human MCs and basophils, one containing
the β-chain and one lacking the β-chain [11]. The
β-chain-containing FcεRI is also expressed on human
eosinophils, whereas murine eosinophils do not express
FcεRI [20,21]. Moreover, the β-chain-lacking FcεRI can
also be found in human monocytes, Langerhans cells
and dendritic cells [22,23]. The exclusive expression of
the β-chain-containing FcεRI in murine cells is because
all three chains have to be present for cell surface ex-
pression [10]. In human cells, expression of the β-chain
is dispensable for surface expression of the FcεRI, how-
ever, the human β-chain has been shown by Kinet and
colleagues to exert two important amplifier functions.
Compared to a human FcεRI that only consists of α-
chain and FcRgamma, the presence of the β-chain
enhances both FcεRI stability and surface expression as
well as activation mechanisms [24,25].Cross-link it – the precipitin way?
Many receptors, like receptor tyrosine kinases and cyto-
kine receptors, require ligand-mediated dimerization for
their activation [26]. The dose-response behavior of such
receptors differs significantly from that of the FcεRI.
These different dose-response curves are sketched in
Figure 1. Whereas increasing concentrations of growth
factors result in a saturated response (e.g. production ofcytokines or upregulation of cell surface molecules), the
Ag dose-response curve of the FcεRI is a bell-shaped
one showing weak responses at both low and high Ag
concentrations (e.g. degranulation and proinflammatory
cytokine production) [27,28]. Such a curve is reminis-
cent of the so-called precipitin curves resulting from the
titration of Ag against a fixed amount of antiserum in
solution (a.k.a. Heidelberger curves) [29]. In such an
assay, only an optimal ratio between Ag and Ab (called
the zone of equivalence) results in the formation of a
visible precipitate, whereas both excess Ab or surplus Ag
prevents formation of a visible precipitate. In the typical
laboratory situation, MCs are preloaded with IgE
(usually of one specificity, such as anti-dinitrophenyl
(DNP) IgE) and then are stimulated with different
concentrations of the respective multivalent Ag, such as
DNP30-40-HSA [27]. Alternatively, cross-linking can be
induced by using anti-IgE immunoglobulins. Because of
the similarities between the Ag/IgE-induced bell-shaped
dose-response curves obtained with MCs and basophils
and the in-solution precipitin curves, interpretation of
the bell-shaped Ag/IgE-induced dose-response curve
was often as sketched in Figure 2. Specifically, a sub-
optimal dose of multivalent Ag (i. e. a high Ab/Ag ratio)
was thought to cross-link only a few IgE-bound FcεRIs,
resulting in a weak activation of downstream signaling
pathways and effector functions (Figure 2A). An optimal
Ag concentration, reflecting the zone of equivalence,
was thought to optimally cross-link all IgE-bound
receptors, thus causing strong activation of Ag-triggered
signaling pathways and maximal induction of effector
functions (Figure 2B). Increasing the Ag dose to the so-
called supra-optimal concentration range (i. e. a low Ab/
Ag ratio) was then thought to result in the formation of
monovalent complexes with every IgE binding “its own”
Ag and thus Ag-mediated cross-links between different
IgE-bound FcεRIs were lost (Figure 2C). Similar to the
sub-optimal situation, only marginal execution of ef-
fector functions combined with weak activation of
downstream signaling pathways would thus be attained.
The precipitin-type model of FcεRI regulation revisited
In 1973, Becker et al. investigated IgE/FcεRI redistribu-
tion and histamine release in human basophils in re-
sponse to increasing concentrations of anti-IgE Abs [30].
They found that histamine release only occurred in the
presence of sub-optimal to optimal levels of anti-IgE,
whereas IgE/FcεRI redistribution was mainly observable
at higher, supra-optimal concentrations of cross-linking
agent [30]. This interesting finding was re-addressed by
Magro and Alexander using a different approach [31]. In
their experiments they studied histamine release from
leukocytes of ragweed sensitive donors, again using anti-
IgE Abs to cross-link IgE-bound FcεRIs. They were
Figure 2 The precipitin-type model-a first attempt to explain FcεRI dose-response behavior. (A) A sub-optimal dose of multivalent Ag
would only cross-link a minor fraction of IgE-bound FcεRIs and result in only weak downstream signaling and induction of effector functions. (B)
An equivalent Ag concentration optimally would cross-link all IgE-bound receptors and cause maximal activation of Ag-triggered signaling
pathways and effector functions. (C) High, supra-optimal concentrations of multivalent Ag were initially thought to result in the formation of
monovalent complexes with every IgE binding “its own” Ag. Thus, cross-linking of IgE-bound FcεRI should not occur. Comparable to the sub-
optimal situation only weak signaling and execution of effector functions would be the outcome. Of note, this model of FcεRI activation based
on the precipitin curve of in-solution immunoprecipitation is not supported by experimental data (see text).
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of these anti-IgE Abs and found that for a sub-optimal to
optimal concentration of anti-IgE increasing concen-
trations of the monomeric Fab fragments inhibited the
release of histamine. This was expected since the
monomers reduced receptor cross-linking by the intact
anti-IgE Abs. At supra-optimal concentrations of anti-IgE
Abs, however, increasing concentrations of the monomerenhanced histamine release. Thus, they concluded that the
descending portion of the dose-response curve might be
the result of an active turn-off mechanism caused by an ex-
cess of bridging rather than the reduced bridging due to
monovalent interactions depicted in the model in Figure 2C
[31]. Of note, the model shown in Figure 2 was only based
on similarity to the Heidelberger curves of in-solution
immunoprecipitation and not on experimental data.
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FcεRIs are supra-optimally cross-linked? Baird and
coworkers reported that stimulation of IgE-bound FcεRI
by polyclonal Abs against IgE induced a detergent-
resistant association of these complexes with the cellular
cytoskeleton [32]. In thorough dose-response studies,
the extent of the cytoskeletal association followed the
extent of FcεRI bridging and, more importantly,
continued to increase beyond the anti-IgE concentration
where degranulation was maximal [32]. This strongly
indicated that stimulation of MCs with supra-optimal
Ag concentrations, that results in little or no degranula-
tion, did cause intracellular rearrangements. A further
study by Oliver and colleagues verified that detergent-
insolubility of FcεRI-IgE-Ag complexes did not correlate
with degranulation [33]. Moreover, using inhibitors of
actin polymerization, they could increase degranulation
at supra-optimal Ag concentrations, while detergent-
insolubility was decreased [33]. From these studies they
concluded that Ag-triggered actin polymerization is
more likely related to the termination/inhibition than to
the stimulation of degranulation, in particular at supra-
optimal Ag concentrations [33]. This also suggested that
stronger actin polymerization was induced by supra-
optimal than by optimal doses of Ag. It further indicated
that strong activation of signal transduction events, at
least those related to actin polymerization, occurred at
supra-optimal Ag concentrations. Finally, Seagrave et al.
using scanning electron microscopy showed that optimally
cross-linked FcεRIs redistribute into chains and small
clusters, whereas supra-optimally cross-linked receptors
redistribute into clusters and large aggregates [34]. Again,
large aggregates at high stimulus concentrations were
prevented from forming by adding either monovalent
ligands or actin depolymerizing agents.
Thus, suppressed degranulation in response to supra-
optimal Ag appeared not to be due to reduced FcεRI
crosslinking, as depicted in Figure 2C. This then begged
the question, was the optimal crosslinking of the major-
ity of receptors shown in Figure 2B accurate? To par-
tially address this it was demonstrated, using stable
oligomers of IgE prepared by chemical crosslinking, that
no more than a few hundred trimers or an even smaller
number of higher oligomers are required to induce a
considerable amount of degranulation from RBL-2H3
MCs [35]. Using monoclonal Abs directed against the α-
chain of the FcεRI, a study by Pecht and colleagues not
only demonstrated that FcεRI aggregates as small as
dimers are capable of providing an effective stimulus for
degranulation but that only a small fraction of FcεRI
needs to be cross-linked in order to yield optimal de-
granulation [36]. Also, for basophils, MacGlashan
showed that only a few hundred FcεRI are needed for
meaningful secretion to occur [37].Signal transduction in the supra-optimal world – an
inhibitory signalosome?
All these studies indicated that the bell-shaped dose-
response curve of MC degranulation might not reflect the
level of signaling taking place inside the cells. Thus, it was
important to elucidate the signaling pathways controlling
MC activation in response to differing concentrations of
Ag. A critical step in regulating IgE-induced degranulation
is the release of intracellular Ca2+ ions from the ER with
subsequent influx of extracellular Ca2+ via store-operated
Ca2+ (SOC) channels [7,38,39]. This response was shown
to follow the bell-shaped dose-response curve with weak
Ca2+ mobilization in response to sub- as well as supra-
optimal Ag concentrations and strong responses after op-
timal cross-linking [27]. Interestingly, Ca2+ mobilization at
supra-optimal was not simply weaker than at optimal Ag
concentrations, but the sustained pattern (optimal)
changed to a transient one (supra-optimal), suggesting ac-
tive negative regulation. Consistent with this, early overall
tyrosine phosphorylation events were slightly enhanced in
supra-optimally vs. optimally stimulated MCs [27,40].
Particularly, tyrosine phosphorylation of a 145 kDa
protein was increased in parallel to the Ag levels and
this protein was identified as the SH2-containing
inositolpolyphosphate 50-phosphatase, SHIP1, a critical
negative regulator of PI3K signaling [27,41,42]. SHIP1
hydrolyzes phosphatidylinositol-3,4,5-trisphosphate (PIP3),
the product of the PI3K-catalyzed reaction, to yield
PI-3,4-P2 [43,44]. This indicated that SHIP1 was involved
in the regulation of the descending part of the dose-
response curve and, indeed, SHIP1-deficient bone
marrow-derived MCs (BMMCs) only showed weak or no
reduction of degranulation in response to supra-optimal
antigen concentrations. Correlating with this, SHIP1-
deficient BMMCs, even at supra-optimal conditions,
showed sustained Ca2+ mobilization [27].
Related to this, the SFK Lyn has been shown to phos-
phorylate and activate SHIP1 in MCs and degranulation
studies with Lyn−/− BMMCs have revealed that these
cells do not display the descending part of the bell-
shaped degranulation curve [45]. Interestingly, Lyn has
also been shown to tyrosine phosphorylate protein kin-
ase C-δ (PKC-δ) and complexes of Lyn with SHIP1 and
PKC-δ have been reported [46-48]. Relevant to this,
Leitges et al. observed augmented Ag-triggered degranu-
lation in PKC-δ-deficient BMMCs, in particular in re-
sponse to supra-optimal stimulus concentrations [47].
These data strongly suggest the existence of an inhibi-
tory signalosome, which appears to be particularly
active when MCs are stimulated by supra-optimal Ag
concentrations.
How could one envision the functional coupling be-
tween supra-optimally cross-linked FcεRIs and such an
inhibitory signalosome? Intriguingly, the β-subunit of
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and colleagues as the amplifier of FcεRI-mediated activa-
tion signals [25,49], has been found by different labora-
tories to be most highly tyrosine-phosphorylated in
response to high Ag concentrations [27,50,51]. In this
respect, in a very elegant and thorough study, Xiao et al.
demonstrated that Lyn was most activated under supra-
optimal conditions, resulting in pronounced β-subunit
ITAM as well as SHIP1 tyrosine phosphorylation and
suppressed degranulation as well as cytokine production
[51]. Importantly, there are two differences between the
β-chain and FcRgamma ITAMs, namely the β-ITAM has
a shorter spacer between its two YXXL sequences (six
amino acids (β) vs. seven amino acids (FcRgamma)),
and the spacer region of the β-chain contains an
additional tyrosine residue. Thus, the β-subunit via its
unique ITAM may utilize Lyn to negatively regulate
downstream events in response to supra-optimal
Ag concentrations [51]. This puts the FcεRI β-chain and
the SFK Lyn at the center of initiation of suppressive
FcεRI-mediated signaling and SHIP1, by controlling the
PI3K pathway, as one of the important downstream
regulators of this response. However, there are certainly
more signaling proteins involved in this process, such as
PKC-δ mentioned above [47].
Interestingly, analyzing GPVI-mediated dense granule
secretion from platelets, Kunapuli and coworkers found
that functional interactions between Lyn, PKC-δ, and
SHIP1 negatively regulate this process as well [52]. GPVI
is a receptor for collagen on platelets that triggers signal-
ing via an associated FcRgamma [53]. Since no FcεRI
β-chain interacts with this receptor complex, the inhibi-
tory signalosome comprising Lyn, PKC-δ, and SHIP1
appears to be capable of acting in a β-chain ITAM-
independent manner. This is intriguing since the unique
tyrosine residue between the canonical ITAM tyrosines
of the β-chain has been shown to be very important for
interaction with SHIP1 [54]. Nevertheless, this suggests
that such an inhibiting/attenuating mechanism can also
be functional in cells which only express an FcεRI
lacking the β-chain, such as Langerhans and dendritic
cells [22].
In MCs, two additional prominent PIP3 phosphatases
are expressed that participate in regulation of the PI3K
pathway, namely the 50-phosphatase SHIP2 and the
30-phosphatase PTEN. SHIP2 has been knocked-down
by shRNA in BMMCs and shown to result in stronger
FcεRI-induced degranulation at every Ag concentration
tested, compared to cells treated with control shRNA
[55]. However, the effect was most pronounced at
optimal Ag concentrations and only marginal at supra-
optimal Ag concentrations. Also, in contrast to
SHIP1-deficient cells, there was no effect of SHIP2 re-
duction on Ag-triggered Ca2+ mobilization [55]. On theother hand, SHIP2 knock-down resulted in enhanced
microtubule reorganization, which might explain the
observed positive effect on degranulation in the absence
of augmented Ca2+ mobilization [56]. These results
indicate that SHIP1 is more involved than SHIP2
in repressing supra-optimal Ag-induced degranulation.
PTEN, a prominent tumor suppressor, was also
knocked-down by an shRNA approach in human MCs
and cells with reduced PTEN expression were shown to
react with augmented Ca2+ mobilization as well as de-
granulation in response to FcεRI activation [57]. Unfor-
tunately, titration of cross-linking Ag was not extended
to the supra-optimal range and thus, no statement can
be made at present on PTEN’s role in repressing de-
granulation at very high Ag concentrations. However,
this analysis did show that PTEN (and not SHIP1 nor
SHIP2) is crucially involved in the “homeostatic” control
of PIP3 levels in unstimulated MCs [57].
How SHIP1 controls degranulation in response to
supra-optimal Ag concentrations is not entirely clear at
the moment. Because of its structure, SHIP1 incorporates
catalytic as well as adaptor functions [58]. Even on the
basis of its catalytic activity two mechanisms, not neces-
sarily mutually exclusive, could be responsible. First,
by hydrolyzing PIP3, SHIP1 would suppress various
PIP3-dependent molecules/pathways, one or more of them
critically involved in Ca2+ mobilization and degranulation
(e.g. phospholipase C-γ1 (PLC-γ1), PLC-γ2, and the
tyrosine kinase Btk [7,59]). Second, by hydrolyzing
PIP3, PI-3,4-P2 is generated, which is known to specifically
interact with PH-domains of certain signaling proteins,
e.g. the adaptor proteins Bam32/DAPP1, TAPP1, and
TAPP2 [60]. Related to this, Bam32-deficiency has been
demonstrated to result in augmented Ca2+ mobilization
and degranulation in response to supra-optimal Ag
concentrations, suggesting that Bam32 represents an
effector of SHIP1’s negative activity [61]. Intriguingly,
compared to wild-type BMMCs Bam32-deficient BMMCs
show reduced Lyn and SHIP1 phosphorylation in response
to Ag, indicating the presence of so far uncharacterized
feed-back mechanisms [61].
With respect to SHIP1’s adaptor or scaffolding func-
tion, increasing numbers of interaction partners of
SHIP1 have been and continue to be identified. SHIP1
contains an N-terminal SH2-domain, a centrally located
50-phosphatase domain, and a C-terminus containing
several proline-rich sequences as well as two NPxY
motifs [58]. The SH2-domain is capable of binding
to the phosphorylated ITAM sequences of the FcεRI
β-chain and FcRgamma [62,63]. In keeping with this,
additional ITAM sequences have been demonstrated to
be bound by the SHIP1 SH2-domain [64-66]. Three of
the proline-rich motifs in SHIP1’s C-terminus show
good consensus for binding to SH3-domains of other
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such as Grb2, CIN85, and Src kinase [67-69]. This might
suggest that Lyn via its SH3-domain can also interact
with SHIP1 in the context of the inhibitory signalosome.
Indeed, SHIP1 could be pulled-down from MC lysates
by means of a GST-SH3 (Lyn) fusion protein (unpub-
lished data). Recently, a pleckstrin homology-related do-
main has been identified that is present N-terminal to the
50-phosphatase domain and shown to mediate membrane
localization of SHIP1 by binding to PIP3 [70].
Finally, proteins containing so-called phosphotyrosine-
binding (PTB)-domains, such as the adaptor proteins
Shc and p62Dok1, have been demonstrated to bind to
SHIP1’s C-terminal NPxY motifs upon their phosphoryl-
ation [71-73]. Since Shc contains both a PTB-domain as
well as an SH2-domain, it was thought initially that Shc
took SHIP1 to the FcεRI. However, analysis of SHIP1-
deficient BMMCs suggested a different binding order
since FcεRI-mediated Shc tyrosine phosphorylation was
dependent on SHIP1 expression [74]. Thus, Shc might
be involved in limiting SHIP1’s activity at the receptor
by “tearing” it away upon Shc’s tyrosine phosphorylation
by Lyn. Shc, however, has also been implicated as a
linker between SHIP1 and PKC-δ by binding to SHIP1
via its PTB-domain and to PKC-δ by means of its
SH2-domain [47]. The adaptor protein p62Dok1, a well-
known interaction partner of the GTPase-activating
protein RasGAP, has also been shown to bind to SHIP1
and inhibit p21Ras and hence, be a negative regulator of
the canonical MAPK pathway (Erk1/2) [72,73]. Interest-
ingly, Erk1/2 might positively regulate FcεRI-mediated
MC degranulation via two different pathways. Pecht and
colleagues have reported that Erk1 is part of a feed-
forward loop positively controlling Syk activity upon
FcεRI triggering [75]. Pharmacologic inhibition of the
Erk kinase MEK suppressed Ag-induced MC degranula-
tion [75]. This effect was recently corroborated with
novel MEK inhibitors with higher selectivity [76]. An-
other mechanism by which Erk1/2 could positively regu-
late MC degranulation is suggested by an interesting
finding by Pozo-Guisado et al. They demonstrated that
Erk1/2 can phosphorylate STIM1, an important calcium
sensor in the membrane of the endoplasmic reticulum,
and thereby positively modulate store-operated calcium
entry, which is mandatory for degranulation to occur
[38,77]. Since the p62Dok1-SHIP1 interaction depends
on SHIP1 tyrosine phosphorylation [73] and SHIP1 tyro-
sine phosphorylation is enhanced upon supra-optimal
FcεRI triggering [27], Erk1/2 activity could be reduced,
contributing to the lack of degranulation under such
conditions. Thus, by combining catalytic as well as
adaptor functions SHIP1 has the potential to contribute
to the regulation of MC activation under supra-optimal
Ag conditions in several ways.As far as other possible negative regulators of supra-
optimal FcεRI-induced MC degranulation are concerned,
Xiao et al. showed that both SHIP1 and SHP-1 interacted
with the FcεRI β-chain and that their phosphorylation was
controlled by Lyn [51]. However, studies to date using
MCs from different mouse models (motheaten (me) mice
[78] and viable motheaten (mev) mice [79]) have not un-
equivocally confirmed a negative role for SHP-1 with
respect to degranulation. Nakata et al. compared BMMCs
from wild-type and me mice and measured decreased
Ca2+ mobilization and degranulation in me BMMCs in re-
sponse to Ag [78]. On the other hand, Zhang et al. studied
BMMCs from mev mice, which were found to degranulate
in an augmented fashion compared to wild-type BMMCs
[79]. The observed differences might be due, in large part,
to the diverse effects on protein expression of the different
mutations within the gene coding for SHP-1 [80]. Unfor-
tunately, in these SHP-1-related studies, like so many
other FcεRI-induced studies to date, Ag dose-responses
were not extended to the supra-optimal range.
The Cbl family of E3 ubiquitin-protein ligases com-
prises three mammalian members, c-cbl, Cbl-b, and
Cbl-c. These proteins poly-ubiquitinate various cellular
proteins, thereby targeting them for proteasomal degrad-
ation [81]. Applying overexpression of c-cbl in the
RBL-2H3 MC line, Ota and Samelson previously showed
that c-cbl is able to negatively affect MC degranulation
by inhibiting the tyrosine kinase Syk [82]. However, a
comparison of wild-type and c-cbl-deficient BMMCs did
not yield differences in Ag-triggered degranulation [83].
On the other hand, the same study revealed signifi-
cant differences between wild-type and Cbl-b-deficient
BMMCs, indicating non-redundant functions of Cbl fam-
ily members in MCs. In response to Ag, enhanced tyrosine
phosphorylation of the FcεRI ITAMs, Syk, and PLC-γ1/2
as well as Ca2+ mobilization was shown in Cbl-b-deficient
BMMCs. This resulted in augmented degranulation at
every Ag concentration studied with the most prominent
effect at high, supra-optimal concentrations [83], sug-
gesting that Cbl-b is involved in the negative control of
MC activation in response to supra-optimal cross-linking.
Interestingly, CIN85 (Cbl-interacting protein of 85-kDa)
was shown to interact with Cbl-b and SHIP1, suggesting
the presence of an additional SHIP1-containing inhibitory
signalosome ([69,84] & unpublished results). Ag stimula-
tion of RBL-2H3 MCs caused co-translocation of Cbl-b,
Lyn, and the FcεRI into lipid rafts [85]. Overexpression of
a lipid raft-anchored form of Cbl-b resulted in severe re-
duction of Ag-triggered tyrosine phosphorylation of the
FcεRI ITAMs, Syk, and PLC-γ1/2, Ca2+ mobilization, and
degranulation [85]. Unexpectedly, degranulation was least
affected at high antigen concentrations suggesting differ-
ential functions of raft- and non-raft-localized Cbl-b with
respect to supra-optimal stimulation. Interestingly, Jnk
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lipid raft-anchored form of Cbl-b, whereas other MAPKs
(Erk, p38) were not [85], and Jnk1 was suggested recently
to be important for MC degranulation [86]. Again, thor-
ough dose-response studies are lacking for a further
evaluation of Jnk function in response to supra-optimal
Ag stimulation.
FcεRI and FcγRIIB (CD32) – brothers in spirit
Immune complex-induced coaggregation of the FcεRI
with the inhibitory, low-affinity receptor for IgG,
FcγRIIB (CD32), results in suppression of FcεRI-
mediated MC activation [87]. In contrast to the FcεRI,
FcγRIIB is a single-chain receptor containing extracellu-
lar IgG-binding immunoglobulin-like domains, a trans-
membrane region, and an intracellular domain that
contains an immunoreceptor tyrosine-based inhibition
motif (ITIM). The tyrosine residue within the ITIM is
phosphorylated by Lyn, which is activated via FcεRI
cross-linking [88]. Upon ITIM tyrosine phosphorylation,
SHIP1 is able to bind to it by means of its SH2-domain,
thus contributing to the down-regulation of PI3K-
mediated activation events [89,90]. SHIP1 then gets
phosphorylated by Lyn as well and is able to recruit a
complex consisting of p62Dok1 and RasGAP, thereby
negatively regulating the canonical MAPK pathway
[72,73]. Interestingly, two crucial elements of FcγRIIB
function, Lyn and SHIP1, are central to the suppression
of FcεRI signaling at supra-optimal Ag concentrationsFigure 3 Activating and inhibitory proteins shape the outcome of Fcε
activation of the FcεRI generates both positive and negative signals, which
concentration both types of signals are generated, however, their ratio and
Ag concentrations preferentially engage activating signaling elements (gre
act proximal to the receptor; Btk, PLC-γ, and STIM1 control Ca2+ mobilizatio
signaling elements are increasingly recruited (red triangle and proteins ind
signalosome; PKC-δ, Bam32, Cbl-b, and actin transduce suppressive signals
an attenuating element depending on the Ag dose (see text).(this review). Moreover, not only is FcεRI function nega-
tively regulated by submembraneous filamentous actin,
but also FcγRIIB-dependent negative regulation is
dependent on this cytoskeletal component [91]. Given
such similarities it is tempting to suggest that one might
be able to transfer mechanisms from one system to the
other. PKC-δ could participate in translating FcγRIIB’s
negative function and the SHIP1-p62Dok1-RasGAP
complex might be involved in supra-optimal FcεRI
signaling. In fact, inducible interactions of SHIP1,
p62Dok1, and RasGAP can be observed in response to
FcεRI triggering (unpublished data). However, one im-
portant difference between SHIP1 binding to FcγRIIB vs.
FcεRI is that binding of the SHIP1 SH2-domain to the
phosphorylated ITIM is of high affinity whereas it is of
low affinity to ITAM sequences [66]. Moreover, the
FcγRIIB-SHIP1 interaction is stabilized by the small
adaptor protein Grb2, which binds to SHIP1 via an
SH3-domain and by means of its SH2-domain to a sec-
ond tyrosine-containing motif within the cytoplasmic
domain of FcγRIIB [92]. The reason for this difference in
affinity may lie with the distinct actions of SHIP1 on
FcεRI- and FcγRIIB-induced signaling. The task of
SHIP1 at the FcγRIIB is to “simply” stop cellular activa-
tion, quickly and completely. Since SHIP1 is engaged
not only in response to supra-optimal triggering of the
FcεRI but also during its activation by sub-optimal to
optimal Ag concentrations [74], SHIP1’s function here is
more an attenuating rather than an inhibitory one.RI stimulation by different Ag concentrations. The Ag-triggered
are integrated to determine the quantity of the response. At every Ag
composition differs depending on the antigen dose. Low to optimal
en area and proteins indicated there; the tyrosine kinases Lyn and Syk
n). In response to high, supra-optimal Ag concentrations negative
icated there; FcεRIβ, Lyn, and SHIP1 are central to the inhibitory
at supra-optimal Ag). Note that the SFK Lyn is both an activating and
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exclusive.
The whole picture (?)
Without a doubt the field has come a long way since the
precipitin-type model of supra-optimal FcεRI activation.
As stated in this review, several proteins can be assigned
inhibitory functions in response to supra-optimal Ag
concentrations (Figure 3). However, one can assume that
there are more regulatory proteins to be discovered. To
accomplish the bell-shaped dose-response curve of
FcεRI-mediated MC activation, both positive and nega-
tive signals have to be generated and integrated to deter-
mine the quantity as well as the quality of the response.
Thus, altered positive signaling might result in stronger
attenuation at high Ag concentrations. This was shown
comparing Ag-triggered histamine release in wild-type,
Lyn-deficient, and Btk-deficient BMMCs. Whereas
Lyn-deficient BMMCs showed no reduction of degranu-
lation at high Ag concentrations, compared to wild-type
cells, Btk-deficient BMMCs exerted stronger attenuation
than wild-type BMMCs [93], consistent with the
accepted positive regulatory role for Btk in FcεRI signal-
ing [94]. A further interesting point is the differential
dose-response behavior of Ag-triggered MCs with re-
spect to different pro-inflammatory effector functions.
Both immediate degranulation and subsequent produc-
tion of pro-inflammatory cytokines (e.g. IL-6 and
TNF-alpha follow a bell shape. However, the descending
part of the curve is significantly steeper concerning
cytokine production [27,28,95]. Moreover, Rivera and
coworkers elegantly demonstrated that Ag-induced
mediators, such as various cytokines and chemokines,
needed different Ag concentrations for their optimal
expression [96]. This strongly suggests that there is not
one activating and one inhibitory signal, but for different
MC responses there might be specially balanced signal-
ing pathways or networks.
Conclusions
The bell-shaped dose-response behavior represents a re-
markable feature of the FcεRI. Nature provides us with
an efficient shut-off mechanism at high, supra-optimal
Ag concentrations, which could be employed to alleviate
allergic symptoms. By deciphering the molecular lan-
guage of inhibitory signaling in response to supra-
optimal Ag concentrations one might identify novel
targets for pharmacologic therapeutic interventions to
benefit patients with acute and chronic allergic diseases.
A deeper understanding of this mechanism(s) should
also help to elucidate the molecular events that occur
during hyposensitization of allergy patients. Finally, the
bell-shaped dose response pattern is not unique to the
FcεRI, but can also be found with other receptors thatsignal in an ITAM-dependent manner, such as the
FcγRIII (CD16) and the B cell antigen receptor [97,98].
Thus, improving our understanding of the regulation of
FcεRI signaling will also enhance our understanding of
other immunologically important receptors.
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